CS1001 monoclonal antibody

BIOLOGICAL3 trials

Sponsors

CStone Pharmaceuticals

Conditions

Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNon Small Cell Lung CancerNon-Small Cell Lung Cancer Stage III

Phase 3

A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

CompletedNCT03728556

CStone PharmaceuticalsNon-Small Cell Lung Cancer Stage III

Start: 2018-10-26End: 2023-04-03Updated: 2023-06-15

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

CompletedNCT03789604

CStone PharmaceuticalsNon Small Cell Lung Cancer

Start: 2018-12-13End: 2026-07-01Updated: 2026-08-18

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

CompletedNCT03802591

CStone PharmaceuticalsGastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2019-03-28End: 2023-09-22Updated: 2023-11-29

Related Papers

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.

2025-06-134 citations

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.

2025-04-0133 citations

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.

2023-06-1529 citations

A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2022-06-017 citations

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.

2022-01-14179 citations

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.

2022-01-14175 citations

Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.

2022-01-0513 citations

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.

2020-10-0112 citations

Platinum-based chemotherapy (chemo) with CS1001, an anti-PD-L1 antibody, for first-line advanced non-small cell lung cancer (NSCLC): Preliminary results from phase Ib cohorts of CS1001-101 study.

Journal of Clinical Oncology2020-05-20

Antibodies to watch in 2020.

2020-01-01328 citations

Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).

Journal of Clinical Oncology2019-05-202 citations